Sign up to save your podcasts
Or
Share Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma
ATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple myeloma according to research reported from the Pavo study at the 2017 American Society of …
View all episodes
By AudioMedica.comATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple myeloma according to research reported from the Pavo study at the 2017 American Society of …